Found: 28
Select item for more details and to access through your institution.
Randomized dose-ranging study of a budesonide metereddose inhaler by using co-suspension delivery technology in asthma.
- Published in:
- Allergy & Asthma Proceedings, 2018, v. 39, n. 5, p. 350, doi. 10.2500/aap.2018.39.4155
- By:
- Publication type:
- Article
Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 223, doi. 10.1002/cpdd.585
- By:
- Publication type:
- Article
Franco-British disparities in medicine.
- Published in:
- Journal of the Royal Society of Medicine, 1981, v. 74, n. 8, p. 605, doi. 10.1177/014107688107400810
- By:
- Publication type:
- Article
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS.
- Published in:
- International Journal of COPD, 2021, v. 16, p. 179, doi. 10.2147/COPD.S286087
- By:
- Publication type:
- Article
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
- Published in:
- International Journal of COPD, 2020, v. 15, p. 99, doi. 10.2147/COPD.S229794
- By:
- Publication type:
- Article
Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
- Published in:
- International Journal of COPD, 2020, v. 15, p. 43, doi. 10.2147/COPD.S223638
- By:
- Publication type:
- Article
Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.
- Published in:
- International Journal of COPD, 2019, v. 14, p. 2993, doi. 10.2147/COPD.S220861
- By:
- Publication type:
- Article
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
- Published in:
- International Journal of COPD, 2019, v. 14, p. 2979, doi. 10.2147/COPD.S220850
- By:
- Publication type:
- Article
Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.
- Published in:
- International Journal of COPD, 2018, v. 13, p. 2969, doi. 10.2147/COPD.S171835
- By:
- Publication type:
- Article
Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
- Published in:
- International Journal of COPD, 2018, v. 13, p. 1965, doi. 10.2147/COPD.S166455
- By:
- Publication type:
- Article
Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
- Published in:
- International Journal of COPD, 2018, v. 13, p. 1483, doi. 10.2147/COPD.S164281
- By:
- Publication type:
- Article
Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.
- Published in:
- International Journal of COPD, 2018, v. 13, p. 1187, doi. 10.2147/COPD.S159246
- By:
- Publication type:
- Article
Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
- Published in:
- International Journal of COPD, 2018, v. 13, p. 945, doi. 10.2147/COPD.S154988
- By:
- Publication type:
- Article
Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease
- Published in:
- BMC Pulmonary Medicine, 2014, v. 14, n. 1, p. 118, doi. 10.1186/1471-2466-14-118
- By:
- Publication type:
- Article
Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
- Published in:
- 2017
- By:
- Publication type:
- journal article
24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2020, v. 14, p. 1, doi. 10.1177/1753466620916990
- By:
- Publication type:
- Article
Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2020, p. 1, doi. 10.1177/1753466620916990
- By:
- Publication type:
- Article
Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 6, p. 579, doi. 10.1007/s40261-021-01040-7
- By:
- Publication type:
- Article
Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
- Published in:
- 2020
- By:
- Publication type:
- journal article